138 related articles for article (PubMed ID: 9181232)
1. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
3. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
4. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
5. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
7. Nonseminomatous germ cell tumors of the testis: current concepts and controversies.
Sheinfeld J
Urology; 1994 Jul; 44(1):2-14. PubMed ID: 7518979
[No Abstract] [Full Text] [Related]
8. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
de Bruijn HW; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Marrink J; Ockhuizen T
Cancer; 1985 Feb; 55(4):829-35. PubMed ID: 2578303
[TBL] [Abstract][Full Text] [Related]
9. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
10. Observations after orchiectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Kuo JY; Chin T; Hsieh YL; Lin AT; Chang YH; Wei C; Chen KK; Chang LS
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):356-61. PubMed ID: 10389293
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
14. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
Davis BE; Herr HW; Fair WR; Bosl GJ
J Urol; 1994 Jul; 152(1):111-3; discussion 114. PubMed ID: 7515445
[TBL] [Abstract][Full Text] [Related]
15. TRA-1-60: a new serum marker in patients with germ-cell tumors.
Marrink J; Andrews PW; van Brummen PJ; de Jong HJ; Sleijfer DT; Schraffordt Koops H; Oosterhuis JW
Int J Cancer; 1991 Sep; 49(3):368-72. PubMed ID: 1717384
[TBL] [Abstract][Full Text] [Related]
16. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
17. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor markers and testicular germ cell tumors: a primer for radiologists.
Marshall C; Enzerra M; Rahnemai-Azar AA; Ramaiya NH
Abdom Radiol (NY); 2019 Mar; 44(3):1083-1090. PubMed ID: 30539249
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
